Davis Launches Effort to Promote Innovation and Sustainability of America's Small Biotechnology Industries


March 16, 2010

Congressman Danny K. Davis Launches Effort to Promote Innovation and Sustainability of America’s Small Biotechnology Industries

to Develop New Medicines to Cure Diseases




For Immediate Release


March 16, 2010


Congressman Danny K. Davis (IL-7th) introduced H.Res.1179, last Friday, March 12, 2010, to support small business biotechnology firms in cultivating innovative therapies to treat a variety of life threatening conditions, including pandemic diseases.  The legislation encourages Federal agencies to develop a coordinated, national approach to the small biotechnology sector to improve resources and funding mechanisms to preserve and enhance the intellectual capacity of these firms.




Rep. Davis said, “Many states have a variety of biotechnology companies that are vital to the health and well-being of the people and the economy of a state.  This is a non-partisan issue and I ask my colleagues, both Democrats and Republicans, to join me in this effort.  Biotechnology is an important contributor to the jobs and intellectual capital.  It promotes healthcare innovation across the country and improves America’s ability to compete in a global marketplace.” 




The legislation encourages therapies and new drug development to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases, including those in medically-underserved communities. The key to the legislation is Congressional support of point-of-care therapeutics and diagnostics by emerging and small business technology firms for domestic and global use.  




Many small biotechnology firms have come together in support of this initiative as part of a concerted effort to save the small biotechnology industry that has been hard hit by the nation’s economic downturn.